Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 30;6(10):e778.
doi: 10.1097/HS9.0000000000000778. eCollection 2022 Oct.

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications

Aaron T Gerds  1 , Prithviraj Bose  2 , Gabriela S Hobbs  3 , Andrew T Kuykendall  4 , Lynn M Neilson  5 , Jinlin Song  6 , Barbara Klencke  5 , Claire N Harrison  7
Affiliations
Editorial

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications

Aaron T Gerds et al. Hemasphere. .
No abstract available

PubMed Disclaimer

References

    1. Tefferi A, Lasho TL, Jimma T, et al. . One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87:25–33. - PMC - PubMed
    1. Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022;15:7. - PMC - PubMed
    1. Bose P, Verstovsek S. The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer. 2016;122:681–692. - PubMed
    1. Kantarjian HM, Silver RT, Komrokji RS, et al. . Ruxolitinib for myelofibrosis–an update of its clinical effects. Clin Lymphoma Myeloma Leuk. 2013;13:638–645. - PMC - PubMed
    1. Talpaz M, Kiladjian JJ. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 2021;35:1–17. - PMC - PubMed

Publication types